Passively transferred neutralizing antibodies (nAbs) have provided definitive protection from HIV-1 infection, yet identification and mechanistic study of these nAbs has not resulted in the development of a protective vaccine. We hypothesize that previous immunogen design efforts have achieved limited success due to their limited scope and restricted focus. The lack of a high-performance screening platform places severe constraints on immunogen design and has impeded the translation of findings from basic science into vaccine development. When attempting to elicit protective antibodies against a highly diverse virus in the context of a disease in which naturally occurring protective immune responses are largely absent, we posit that the scale of technology and methods used must be adequately matched to the scale of the task. Combinatorial, high-throughput protein engineering platforms can achieve the landscape coverage that may be necessary for successful development of a preventative HIV vaccine, and allow us to translate our understanding of nAbs into the induction of protective antibody responses. We therefore propose to develop high-performance protein engineering tools to screen billions of HIV envelope trimer sequence variants according to defined criteria, allowing us to evolve envelope immunogens tailored to effectively present functionally relevant and immunogenic epitopes capable of driving the generation of protective antibodies. The multi-pronged strategy we describe both leverages the growing reagent toolkit for traditional immunogen design, including more than a dozen new broad nAbs, and improved means to functionally parse Abs present in diverse, polyclonal samples;and further explores a complementary strategy based on selective engagement of na?ve and germline antibody repertoires which we believe addresses the fundamental limitation of previous immunogen design efforts and represents an innovative and unbiased forward engineering strategy to induce the generation of neutralizing antibodies. Ultimately, the tools developed by these studies represent adaptable platforms capable of rapidly selecting envelope variants from vast sequence diversity according to flexible design criteria, and may open a path to a fundamental breakthrough in immunogen design by bridging the translational gap that has come to be known as """"""""the nAb problem"""""""".

Public Health Relevance

Our proposed studies aim to improve our understanding of the interaction between the HIV envelope and the immune system, providing new insight into envelope-based vaccine design, facilitating development of a protective vaccine to contain the HIV epidemic.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI102691-01
Application #
8409958
Study Section
Special Emphasis Panel (ZAI1-DR-A (M1))
Program Officer
Onami, Thandi M
Project Start
2012-07-18
Project End
2016-06-30
Budget Start
2012-07-18
Budget End
2013-06-30
Support Year
1
Fiscal Year
2012
Total Cost
$478,260
Indirect Cost
$129,458
Name
Dartmouth College
Department
Type
Schools of Engineering
DUNS #
041027822
City
Hanover
State
NH
Country
United States
Zip Code
03755
Brown, Eric P; Dowell, Karen G; Boesch, Austin W et al. (2017) Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles. J Immunol Methods 443:33-44
Veenhuis, Rebecca T; Freeman, Zachary T; Korleski, Jack et al. (2017) HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells. J Clin Invest :
Fang, Yongliang; Chu, Thach H; Ackerman, Margaret E et al. (2017) Going native: Direct high throughput screening of secreted full-length IgG antibodies against cell membrane proteins. MAbs 9:1253-1261
Hua, Casey K; Ackerman, Margaret E (2017) Increasing the Clinical Potential and Applications of Anti-HIV Antibodies. Front Immunol 8:1655
Easterhoff, David; Moody, M Anthony; Fera, Daniela et al. (2017) Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathog 13:e1006182
Ackerman, Margaret E; Barouch, Dan H; Alter, Galit (2017) Systems serology for evaluation of HIV vaccine trials. Immunol Rev 275:262-270
Boesch, Austin W; Miles, Adam R; Chan, Ying N et al. (2017) IgG Fc variant cross-reactivity between human and rhesus macaque Fc?Rs. MAbs 9:455-465
Huang, Yunda; Ferrari, Guido; Alter, Galit et al. (2016) Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects. J Immunol 197:4603-4612
Ackerman, Margaret E; Mikhailova, Anastassia; Brown, Eric P et al. (2016) Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control. PLoS Pathog 12:e1005315
Boesch, Austin W; Osei-Owusu, Nana Yaw; Crowley, Andrew R et al. (2016) Biophysical and Functional Characterization of Rhesus Macaque IgG Subclasses. Front Immunol 7:589

Showing the most recent 10 out of 22 publications